Published online before print March 17, 2003, doi: 10.1161/01.CIR.0000057979.36322.88
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2003;107:1664.)
© 2003 American Heart Association, Inc.
Basic Science Reports |
Rapamycin Attenuates Load-Induced Cardiac Hypertrophy in Mice
From the Cardiovascular Division, Department of Medicine (T.S., J.R.M., O.T., K.C., W.J.M., S.I.) and Department of Radiology (K.C., W.J.M.), Beth Israel Deaconess Medical Center, and the Department of Cardiology (M.C.S.), Boston Children’s Hospital, Boston, Mass.
Correspondence to Seigo Izumo, MD, Cardiovascular Division, Beth Israel Deaconess Medical Center, 330 Brookline Ave, Boston, MA 02215. E-mail sizumo{at}bidmc.harvard.edu
 |
Abstract |
|---|
 Top Abstract IntroductionMethodsResultsDiscussionReferences |
|---|
Background— Cardiac hypertrophy, or an increase in heart size, is an important risk factor for cardiac morbidity and mortality. The mammalian target of rapamycin (mTOR) is a component of the insulin-phosphoinositide 3-kinase pathway, which is known to play a critical role in the determination of cell, organ, and body size.
Methods and Results— To examine the role of mTOR in load-induced cardiac hypertrophy, we administered rapamycin, a specific inhibitor of mTOR, to mice with ascending aortic constriction. Activity of p70 ribosomal S6 kinase 1 (S6K1), an effector of mTOR, was increased by 3.8-fold in the aortic-constricted heart. Pretreatment of mice with 2 mg · kg-1 · d-1 of rapamycin completely suppressed S6K1 activation and S6 phosphorylation in response to pressure overload. The heart weight/tibial length ratio of vehicle-treated aortic-banded mice was increased by 34.4±3.6% compared with vehicle-treated sham-operated mice. Rapamycin suppressed the load-induced increase in heart weight by 67%. Attenuation of cardiac hypertrophy by rapamycin was associated with attenuation of the increase in myocyte cell size induced by aortic constriction. Rapamycin did not cause loss of body weight, lethality, or left ventricular dysfunction.
Conclusions— mTOR or its target(s) seems to play an important role in load-induced cardiac hypertrophy. Because systemic administration of rapamycin has been used successfully for the treatment of transplant rejection in clinical practice, it may be a useful therapeutic modality to suppress cardiac hypertrophy in patients.
Key Words: hypertrophy • heart failure • signal transduction
|
Introduction |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
The insulin-phosphoinositide 3-kinase (PI3K) pathway plays a critical role in the determination of cell, organ, and body size in Drosophila,1 and PI3K(p110
) and Akt (a downstream effector of PI3K) promote heart growth in transgenic mice.2,3 The target of rapamycin (TOR) has been shown to interact genetically with the PI3K pathway in Drosophila.4,5 Rapamycin is a lipophilic macrolide, which was first identified in a natural product screen as a fungicide isolated from the soil bacterium Streptomyces hygroscopicus.6 In the search for molecules affected by rapamycin, TOR was identified in yeast (reviewed by Gingras et al7). Purification and molecular cloning of mammalian TOR (mTOR) revealed a 290-kDa protein that is closely related to yeast TOR. Rapamycin has effects on growth by forming a gain-of-function inhibitory complex with FKBP12 (FK506-binding protein; MW, 12 kDa).8,9 This complex binds to mTOR and inhibits its function. In response to growth factors and amino acids, mTOR controls the mammalian translational machinery via activation of p70 ribosomal S6 kinase and via inhibition of the eIF4E inhibitor, 4E-BP1.8 p70 ribosomal S6 kinase is a physiological kinase for the 40S ribosomal S6 protein.8,9 In mammals, 2 highly homologous genes, called p70 ribosomal S6 kinase 1 (S6K1) and p70 ribosomal S6 kinase 2 (S6K2), have been identified.10 Rapamycin is a potent inhibitor of S6K1, preventing activation of S6K1 by all known agonists.11 Although S6K1 is not the direct target of rapamycin, it is likely to be a proximal effector, because inactivation of S6K1 by rapamycin occurs within 5 minutes. The inhibitory effects of rapamycin are considered to be highly specific, because the kinase most closely related to S6K, the 90-kDa ribosomal S6 kinase (RSK), is resistant to the drug.11
Rapamycin effectively attenuated hypertrophy of cultured myocytes induced by several growth factors.12,13 Furthermore, S6K1 was activated in a cat model of right ventricular pressure overload, suggesting that mTOR or its target(s) might be involved in load-induced cardiac hypertrophy.14 To determine the role of mTOR or its target(s) in load-induced cardiac hypertrophy, we administered a clinically relevant dose of rapamycin to mice subjected to ascending aortic constriction.
|
Methods |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Generation of Mice With Aortic Stenosis
For aortic-banding experiments, ascending aortic constriction was performed in 12-week-old male FVB/N mice (Charles River Laboratories International, Inc, Wilmington, Mass) as described previously,15 except that mice were anesthetized with pentobarbital sodium salt (60 mg/kg) and the aorta was ligated with a 25-gauge needle. For the sham operation, the aorta was not ligated.
Administration of Rapamycin
Rapamycin (2 mg · kg-1 · d-1) or vehicle was administered intraperitoneally to aortic-banded or sham-operated mice. The dose of rapamycin was based on the literature in which rapamycin was used as an immunosuppressant in mice.16,17 A dose of 2 mg · kg-1 · d-1 in mice is equivalent to a dose of 0.17 mg · kg-1 · d-1 in humans when normalized by body surface area.18 This dose is comparable to the dose of rapamycin used in human studies.19 The solvent for rapamycin was 0.2% sodium carboxymethylcellulose, 0.25% polysorbate-80 in water. Vehicle was the solvent for rapamycin.
Experimental Protocols
Protocol 1
To examine whether acute pressure overload induces S6K1 activation and S6 phosphorylation, aortic-banded or sham-operated mice were killed 1, 4, 8, 24, and 48 hours and 1 week after surgery.
Protocol 2
To examine the effect of rapamycin on S6K1 activity, S6 phosphorylation, c-Jun NH2-terminal kinase 1 (JNK1) activity, and glycogen synthase kinase-3ß (GSK3ß) phosphorylation, rapamycin- or vehicle-treated mice were subjected to the sham or banding operation and killed 4 hours after surgery. Rapamycin or vehicle was given on the day before surgery and 3 hours before surgery.
Protocol 3
To examine the effect of rapamycin on load-induced cardiac hypertrophy, we treated aortic-banded and sham-operated mice with rapamycin or vehicle for 1 week after surgery. Rapamycin or vehicle treatment was started on the day before the operation, injected 3 hours before surgery, and then injected daily for 1 week. Survival was monitored, echocardiography was performed 6 days after surgery, and mice were killed 7 days after surgery. Body weight, heart weight, lung weight, and tibial length were measured. Heart tissues were used for analysis of cell size and gene expression.
Protocol 4
To assess hemodynamic loading conditions, left ventricular (LV) pressures were measured in sham or banded mice after receiving vehicle or rapamycin for 1 week (as described in protocol 3). Mice were then killed, and heart weight and tibial length were measured.
Echocardiography
Echocardiography was performed as described previously,2 except that 2,2,2-tribromoethanol (Aldrich; 0.4 to 0.6 mg/kg) was used for anesthesia.
Hemodynamic Measurements
Mice were anesthetized and ventilated as described for the aortic banding operation. LV pressures were measured by a 1.4F high-fidelity pressure catheter (Millar catheter) inserted through the LV apex. The catheter was secured in the LV apex with a purse-string suture using 5-0 silk. Pressure signals were recorded at 2 kHz for 5 minutes, stored to disk, and analyzed with PowerLab software (Chart 4.1.2, ADInstruments).
Measurement of S6K1 Activity in Heart Tissue
Heart lysates were obtained and S6K1 activity was measured as described previously.3
Measurement of S6 and GSK3ß Phosphorylation
Heart lysates (100 µg) were subjected to SDS-PAGE as described previously.3 To measure S6 phosphorylation, the blots were probed with an anti-phospho S6 antibody (New England Biolabs) followed by an anti-GAPDH antibody (Research Diagnostics). To measure the phosphorylation of GSK3ß, the blots were probed with an anti-phospho GSK3ß antibody (Cell Signaling) followed by an anti-GSK3ß antibody (Transduction Laboratory).
Measurement of JNK1 Activity in the Heart
The activity of JNK1 was measured by immune complex kinase assays as described previously.20
Myocyte Cross-Sectional Area
Hearts were cut at the horizontal short-axis plane, fixed in 4% paraformaldehyde, dehydrated, embedded in paraffin, and sectioned. Heart sections cut at the level of the papillary muscle were selected and used for the measurement of cross-sectional area. The sections were deparaffinized, rehydrated, and incubated for 1 hour at room temperature with FITC-labeled wheat germ agglutinin (Sigma; 1:5 dilution) to visualize myocyte membranes.21 Images of LV cardiomyocyte cell membranes were obtained with a confocal microscope (Bio-Rad). Regions that included the circular shape of capillaries were selected from the epicardial side of the LV free walls. Morphometric analysis was performed with IPLab software (Scanalytics, Inc). Mean values from each mouse were calculated by use of the measurements from 60 to 80 cells from an individual mouse. Next, new mean values (±SEM) for each experimental group were calculated on the basis of the data from the mean values from individual mice and are presented.
Northern Hybridization
Northern hybridization was performed as described previously.2 Mouse atrial natriuretic peptide (ANP)2 cDNA and mouse brain natriuretic peptide (BNP) cDNA22 were used.
Statistical Analysis
All values are expressed as mean±SEM. Differences between the groups were compared by 2-way ANOVA followed by the Fisher’s protected least significant difference post hoc test. A value of P<0.05 was considered significant.
|
Results |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Effect of Acute Pressure Overload on S6K1 Activity and S6 Phosphorylation
First, we examined whether S6K1, a target of mTOR, was activated in response to acute pressure overload (protocol 1). Aortic-banded or sham-operated mice were killed 1, 4, 8, 24, and 48 hours and 1 week after the operation (n=4 for each time point). At 1, 4, and 8 hours after the operation, S6K1 activity in the hearts from sham-operated mice was decreased compared with that from mice that had not undergone surgery (unoperated mice) (Figure 1A). In contrast, S6K1 activity was increased 1 hour after aortic banding, reached its peak at 4 hours, and was similar to baseline levels at 24 hours (Figure 1A).
|
To confirm the activation of S6K1 in heart tissue in response to aortic banding, phosphorylation of S6 was measured (Figure 1B). As seen with S6K1 activity, the amount of phosphorylated S6 in the hearts from sham-operated mice was decreased after the operation compared with unoperated mice. The amount of phosphorylated S6 was markedly increased 4 hours after aortic banding compared with sham-operated animals. Thus, acute pressure overload induced S6K1 activation and S6 phosphorylation in the heart.
Effect of Rapamycin on S6K1 Activity, S6 Phosphorylation, JNK1 Activity, and GSK3ß Phosphorylation
Next, we examined the effects of rapamycin on load-induced S6K1 activation (protocol 2). Because S6K1 activity was highest 4 hours after the banding operation, we examined S6K1 activity in the hearts from rapamycin-treated mice at this time point (Figure 2A). Rapamycin (2 mg · kg-1 · d-1) suppressed basal S6K1 activity as well as that in response to acute pressure overload. Rapamycin completely inhibited basal activity as well as the load-induced increase in S6 phosphorylation (Figure 2B).
|
P<0.05 vs vehicle-treated aortic-banded mice. Mean value of vehicle-treated sham-operated mice was defined as 1 U.We also examined the effect of rapamycin on other signaling molecules in response to aortic banding. Mitogen-activated protein (MAP) kinases are postulated to be mediators of cardiac hypertrophy.23 We examined the activity of extracellular signal-regulated kinase 2 (ERK2), p38 MAP kinase, and JNK1 in aortic-banded hearts 4 hours after the operation. JNK1 was activated 5.6±0.4-fold in vehicle-treated aortic-banded mice compared with vehicle-treated sham-operated mice (Figure 2C). ERK2 or p38 MAP kinase was not significantly activated in the aortic-banded hearts at this time point (data not shown). JNK1 activity was partially but significantly reduced in rapamycin-treated aortic-banded mice compared with vehicle-treated aortic-banded mice. We also examined the phosphorylation of GSK3ß, a well-defined direct target of Akt that has been shown to negatively regulate heart growth.24,25 In the present study, phosphorylation of GSK3ß was not different between aortic-banded and sham-operated mice. Furthermore, rapamycin treatment did not affect the phosphorylation of GSK3ß (Figure 2D).
Effect of Rapamycin on the Load-Induced Increase in Heart Weight
To examine whether rapamycin attenuates load-induced cardiac hypertrophy, we treated aortic-banded mice with rapamycin or vehicle daily for 1 week after surgery (protocol 3). There was no significant difference in mortality between the groups (0 of 6 vehicle-treated sham, 4 of 12 vehicle-treated banded, 1 of 6 rapamycin-treated sham, and 2 of 12 rapamycin-treated banded died within 1 week of the operation). Mice were killed 1 week after the operation. The heart weight/tibial length ratio of aortic-banded mice was increased by 34.4±3.6% compared with vehicle-treated sham-operated mice (Table 1). In contrast, the heart weight/tibial length ratio of rapamycin-treated banded mice was increased by only 11.5±4.4% compared with rapamycin-treated sham mice. Thus, rapamycin suppressed the load-induced increase in heart weight/tibial length ratio by 67%. Rapamycin did not affect body weight, lung weight, or liver weight (Table 1).
|
Effect of Rapamycin on Hemodynamic Loading Conditions
To examine the effect of rapamycin on hemodynamic loading conditions of aortic-banded mice, we measured LV pressures (protocol 4). The peak systolic pressures were relatively low in the present study (Table 2). This can probably be explained by the effects of anesthesia and the invasive technique used to measure LV pressures in open-chest mice. Because aortic-banded mice display signs of pressure overload, including labored respiration and reduced activity, it was not considered feasible to measure blood pressure via the noninvasive tail-cuff method or to use more complicated techniques to measure pressures in closed-chest mice (in such cases, peak systolic pressures are usually higher). It is noteworthy that our values for LV pressures are similar to those reported in a previous study using similar open-chest techniques.26 Importantly, under the same experimental conditions, there was no significant difference in LV systolic or diastolic pressures between vehicle-treated aortic-banded mice and rapamycin-treated aortic-banded mice (Table 2). However, the heart weight/tibial length ratio of rapamycin-treated aortic-banded mice was significantly lower than that of vehicle-treated aortic-banded mice. Thus, rapamycin attenuated load-induced cardiac hypertrophy in the presence of comparable hemodynamic loading conditions.
|
Effect of Rapamycin on Myocyte Cell Size
To examine whether rapamycin changes heart size through the regulation of myocyte cell size, the myocyte cross-sectional area of the LV myocardium was measured in hearts from mice subjected to aortic banding for 1 week (Figure 3). The cell area of vehicle-treated aortic-banded mice was increased by 46.7±6.0% compared with vehicle-treated sham-operated animals. The cell area of hearts from aortic-banded mice treated with rapamycin was increased by 19.9±6.2% compared with rapamycin-treated sham-operated mice. Thus, rapamycin suppressed the load-induced increase in myocyte cell size by 57%. Collectively, this suggests that rapamycin attenuated the load-induced increase in heart size primarily through the regulation of myocyte cell size.
|
Effect of Rapamycin on Cardiac Function of Aortic-Banded Mice
One week after surgery, we examined the effect of rapamycin on cardiac function using echocardiography (Table 3). Rapamycin treatment significantly decreased LV diastolic and systolic diameters in aortic-banded mice. Cardiac contractility, assessed by fractional shortening, was not different between vehicle-treated and rapamycin-treated animals. Thus, rapamycin treatment was associated with a decrease in chamber size and normal systolic function.
|
Effect of Rapamycin on Fetal Gene Expression in Aortic-Banded Mice
Cardiac hypertrophy in response to pressure overload is associated with reactivation of "fetal" genes.27 We previously showed that in cultured rat neonatal myocytes, rapamycin inhibited increases in cell size and protein synthesis stimulated by angiotensin II, but angiotensin II-induced fetal gene expression was not affected by rapamycin.12 We examined the expression of ANP and BNP in the hearts from mice 1 week after the operation (Figure 4). There was no significant difference in the amount of ANP or BNP mRNA between the aortic-banded groups with or without rapamycin.
|
|
Discussion |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
mTOR plays a key role in regulating cell growth.8 In this study, we examined the effect of rapamycin, a specific inhibitor of mTOR,11,28 on pressure overload-induced cardiac hypertrophy. Rapamycin, at a clinically relevant dose, effectively attenuated load-induced cardiac hypertrophy, and this was associated with attenuation of the increase in myocyte cell size. Furthermore, rapamycin did not cause lethality, loss of body weight, or deterioration of cardiac function. To the best of our knowledge, this is the first study to demonstrate that rapamycin can reduce heart size without disturbing cardiac function in vivo.
Rapamycin inhibits angiotensin II and phenylephrine-mediated hypertrophy of cardiac myocytes in vitro, and inhibition of S6K1 has been implicated as a key factor in this response.12,13 In the present study, S6K1 was activated significantly in the heart in response to acute pressure overload in vivo, and rapamycin completely suppressed load-induced S6K1 activation and S6 phosphorylation. Thus, activation of S6K1 seems to be critical for the development of cardiac hypertrophy in response to pressure overload. Another important effector of mTOR, 4E-BP1, may also modulate this response. Phosphorylation of 4E-BP1 results in release of eIF4E, allowing increased formation of the eIF4F translation factor complexes. Rapamycin can inhibit insulin-induced phosphorylation of 4E-BP1 in cardiomyocytes, and this may affect protein synthesis in the heart.29,30
We also examined the effect of aortic banding and rapamycin on a number of other downstream signaling molecules. JNK1 activity increased with banding and was partially but significantly attenuated by rapamycin treatment. Thus, rapamycin, either directly or indirectly, selectively inhibited one of the MAP kinase pathways. It was reported that rapamycin inhibited JNK1 activation in lymphocytes by an unknown mechanism.31 Phosphorylation of GSK3ß, a downstream target of Akt and a negative regulator of heart growth,24,25 was not affected by pressure overload or rapamycin treatment in the present study. By contrast, GSK3ß was shown to be inactivated in hearts of rats in response to aortic banding.32 This discrepancy may be explained by the more severe banding conditions used by Haq et al.32
Rapamycin has been used in the treatment of transplant rejection.19 Recently, it was shown that rapamycin-coated stents potently inhibited restenosis after coronary angioplasty.33 Calcineurin inhibitors, such as cyclosporin A and FK506, have been the mainstays of immunosuppression for solid-organ transplantation. However, the nephrotoxicity of calcineurin inhibitors limits their therapeutic benefit.34 Because rapamycin has a unique mechanism of action distinct from that of calcineurin inhibitors and is associated with less nephrotoxicity,35 it (or its derivatives) might be a useful modality to suppress cardiac hypertrophy. In this study, we have shown that pretreatment of rapamycin effectively prevents load-induced overgrowth of the heart. Future studies are necessary to examine whether rapamycin can regress established cardiac hypertrophy and cardiomyopathy. In addition, because the phosphorylation of S6 is believed to be critical for the translation of specific mRNA species, it would be of interest to examine which mRNA species are inhibited by rapamycin.
|
Acknowledgments |
|---|
This work was supported in part by the American Heart Association, New England Affiliate, Beginning Grant-in-Aid to Dr Shioi and by National Institutes of Health grants AG-61716 and HL-65742 to Dr Izumo. We gratefully acknowledge S. Sehgal (Wyeth-Ayerst) for providing rapamycin, J. Blenis for the GST-S6 plasmid, and S. Ngoy for performing some of the mouse operations.
Received December 28, 2001; revision received December 10, 2002; accepted December 17, 2002.
|
References |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
1. Weinkove D, Leevers SJ. The genetic control of organ growth: insights from Drosophila. Curr Opin Genet Dev. 2000; 10: 75–80.[CrossRef][Medline] [Order article via Infotrieve]
2. Shioi T, Kang PM, Douglas PS, et al. The conserved phosphoinositide 3-kinase pathway determines heart size in mice. 2000; 19: 2537–2548.
3. Shioi T, McMullen JR, Kang PM, et al. Akt/Protein kinase B promotes organ growth in transgenic mice. Mol Cell Biol. 2002; 22: 2799–2809.
4. Zhang H, Stallock JP, Ng JC, et al. Regulation of cellular growth by the Drosophila target of rapamycin dTOR. Genes Dev. 2000; 14: 2712–2724.
5. Oldham S, Montagne J, Radimerski T, et al. Genetic and biochemical characterization of dTOR, the Drosophila homolog of the target of rapamycin. Genes Dev. 2000; 14: 2689–2694.
6. Vezina C, Kudelski A, Sehgal SN. Rapamycin (AY-22,989), a new antifungal antibiotic, I: taxonomy of the producing streptomycete and isolation of the active principle. J Antibiot (Tokyo). 1975; 28: 721–726.[Medline] [Order article via Infotrieve]
7. Gingras AC, Raught B, Sonenberg N. Regulation of translation initiation by FRAP/mTOR. Genes Dev. 2000; 15: 807–826.
8. Schmelzle T, Hall MN. TOR, a central controller of cell growth. Cell. 2000; 103: 253–262.[CrossRef][Medline] [Order article via Infotrieve]
9. Thomas G, Hall MN. TOR signalling and control of cell growth. Curr Opin Cell Biol. 1997; 9: 782–787.[CrossRef][Medline] [Order article via Infotrieve]
10. Shima H, Pende M, Chen Y, et al. Disruption of the p70(s6 k)/p85(s6 k) gene reveals a small mouse phenotype and a new functional S6 kinase. EMBO J. 1998; 17: 6649–6659.[CrossRef][Medline] [Order article via Infotrieve]
11. Chou MM, Blenis J. The 70 kDa S6 kinase: regulation of a kinase with multiple roles in mitogenic signaling. Curr Opin Cell Biol. 1995; 7: 806–814.[CrossRef][Medline] [Order article via Infotrieve]
12. Sadoshima J, Izumo S. Rapamycin selectively inhibits angiotensin II-induced increase in protein synthesis in cardiac myocytes in vitro: potential role of 70-kD S6 kinase in angiotensin II-induced cardiac hypertrophy. Circ Res. 1995; 77: 1040–1052.
13. Boluyt MO, Zheng JS, Younes A, et al. Rapamycin inhibits 1-adrenergic receptor-stimulated cardiac myocyte hypertrophy but not activation of hypertrophy-associated genes: evidence for involvement of p70 S6 kinase. Circ Res. 1997; 81: 176–186.
14. Laser M, Kasi VS, Hamawaki M, et al. Differential activation of p70 and p85 S6 kinase isoforms during cardiac hypertrophy in the adult mammal. J Biol Chem. 1998; 273: 24610–24619.
15. Ding B, Price RL, Borg TK, et al. Pressure overload induces severe hypertrophy in mice treated with cyclosporine, an inhibitor of calcineurin. Circ Res. 1999; 84: 729–734.
16. Blazar BR, Taylor PA, Snover DC, et al. Murine recipients of fully mismatched donor marrow are protected from lethal graft-versus-host disease by the in vivo administration of rapamycin but develop an autoimmune-like syndrome. J Immunol. 1993; 151: 5726–5741.[Abstract]
17. Chen H, Qi S, Xu D, et al. The immunosuppressive effect of rapamycin on mouse small bowel transplantation. Transplantation. 1996; 61: 523–526.[CrossRef][Medline] [Order article via Infotrieve]
18. Chodera A, Feller K. Some aspects of pharmacokinetic and biotransformation differences in humans and mammal animals. Int J Clin Pharmacol Biopharm. 1978; 16: 357–360.[Medline] [Order article via Infotrieve]
19. Saunders RN, Metcalfe MS, Nicholson ML. Rapamycin in transplantation: a review of the evidence. Kidney Int. 2001; 59: 3–16.[CrossRef][Medline] [Order article via Infotrieve]
20. Aoki H, Richmond M, Izumo S, et al. Specific role of the extracellular signal-regulated kinase pathway in angiotensin II-induced cardiac hypertrophy in vitro. Biochem J. 2000; 1: 275–284.
21. Schultz JE, Witt SA, Nieman ML, et al. Fibroblast growth factor-2 mediates pressure-induced hypertrophic response. J Clin Invest. 1999; 104: 709–719.[Medline] [Order article via Infotrieve]
22. Tanaka M, Chen Z, Bartunkova S, et al. The cardiac homeobox gene Csx/Nkx2.5 lies genetically upstream of multiple genes essential for heart development. Development. 1999; 126: 1269–1280.[Abstract]
23. Sugden PH, Clerk A. Cellular mechanisms of cardiac hypertrophy. J Mol Med. 1998; 76: 725–746.[CrossRef][Medline] [Order article via Infotrieve]
24. Cross DA, Alessi DR, Cohen P, et al. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature. 1995; 378: 785–789.[CrossRef][Medline] [Order article via Infotrieve]
25. Antos CL, McKinsey TA, Frey N, et al. Activated glycogen synthase-3ß suppresses cardiac hypertrophy in vivo. Proc Natl Acad Sci U S A. 2002; 99: 907–912.
26. Hoit BD, Ball N, Walsh RA. Invasive hemodynamics and force-frequency relationships in open- versus closed-chest mice. Am J Physiol. 1997; 273: H2528–H2533.[Medline] [Order article via Infotrieve]
27. Izumo S, Nadal-Ginard B, Mahdavi V. Protooncogene induction and reprogramming of cardiac gene expression produced by pressure overload. Proc Natl Acad Sci U S A. 1988; 85: 339–343.
28. Davies SP, Reddy H, Caivano M, et al. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000; 351: 95–105.[CrossRef][Medline] [Order article via Infotrieve]
29. Pham FH, Sugden PH, Clerk A. Regulation of protein kinase B and 4E-BP1 by oxidative stress in cardiac myocytes. Circ Res. 2000; 86: 1252–1258.
30. Wang L, Wang X, Proud CG. Activation of mRNA translation in rat cardiac myocytes to insulin involves multiple rapamycin-sensitive steps. Am J Physiol. 2000; 278: H1056–H1068.
31. Ishizuka T, Sakata N, Johnson GL, et al. Rapamycin potentiates dexamethasone-induced apoptosis and inhibits JNK activity in lymphoblastoid cells. Biochem Biophys Res Commun. 1997; 230: 386–391.[CrossRef][Medline] [Order article via Infotrieve]
32. Haq S, Choukroun G, Kang ZB, et al. Glycogen synthase kinase-3ß is a negative regulator of cardiomyocyte hypertrophy. J Cell Biol. 2000; 151: 117–129.
33. Morice MC, Serruys PW, Sousa JE, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med. 2002; 346: 1773–1780.
34. Ventura HO, Malik FS, Mehra MR, et al. Mechanisms of hypertension in cardiac transplantation and the role of cyclosporine. Curr Opin Cardiol. 1997; 12: 375–381.[Medline] [Order article via Infotrieve]
35. Golbaekdal K, Nielsen CB, Djurhuus JC, et al. Effects of rapamycin on renal hemodynamics, water and sodium excretion, and plasma levels of angiotensin II, aldosterone, atrial natriuretic peptide, and vasopressin in pigs. Transplantation. 1994; 58: 1153–1157.[Medline] [Order article via Infotrieve]
This article has been cited by other articles:
 |
|
 |
|
  G. G. Camici, J. Steffel, I. Amanovic, A. Breitenstein, J. Baldinger, S. Keller, T. F. Luscher, and F. C. Tanner Rapamycin promotes arterial thrombosis in vivo: implications for everolimus and zotarolimus eluting stents Eur. Heart J., June 29, 2009; (2009) ehp259v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Y. Oudit and J. M. Penninger Cardiac regulation by phosphoinositide 3-kinases and PTEN Cardiovasc Res, May 1, 2009; 82(2): 250 - 260. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Zafar, F. A. Belibi, Z. He, and C. L. Edelstein Long-term rapamycin therapy in the Han:SPRD rat model of polycystic kidney disease (PKD) Nephrol. Dial. Transplant., March 25, 2009; (2009) gfp129v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. P. H. Huang, Y. Wang, X. Wang, Z. Wang, and C. G. Proud Blocking eukaryotic initiation factor 4F complex formation does not inhibit the mTORC1-dependent activation of protein synthesis in cardiomyocytes Am J Physiol Heart Circ Physiol, February 1, 2009; 296(2): H505 - H514. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Zhu, M. H. Soonpaa, H. Chen, W. Shen, R. M. Payne, E. A. Liechty, R. L. Caldwell, W. Shou, and L. J. Field Acute Doxorubicin Cardiotoxicity Is Associated With p53-Induced Inhibition of the Mammalian Target of Rapamycin Pathway Circulation, January 6, 2009; 119(1): 99 - 106. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Ha, F. Hua, X. Liu, J. Ma, J. R. McMullen, T. Shioi, S. Izumo, J. Kelley, X. Gao, W. Browder, et al. Lipopolysaccharide-induced myocardial protection against ischaemia/reperfusion injury is mediated through a PI3K/Akt-dependent mechanism Cardiovasc Res, June 1, 2008; 78(3): 546 - 553. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Y. Oudit, Z. Kassiri, J. Zhou, Q. C. Liu, P. P. Liu, P. H. Backx, F. Dawood, M. A. Crackower, J. W. Scholey, and J. M. Penninger Loss of PTEN attenuates the development of pathological hypertrophy and heart failure in response to biomechanical stress Cardiovasc Res, June 1, 2008; 78(3): 505 - 514. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W.-H. Shen, Z. Chen, S. Shi, H. Chen, W. Zhu, A. Penner, G. Bu, W. Li, D. W. Boyle, M. Rubart, et al. Cardiac Restricted Overexpression of Kinase-dead Mammalian Target of Rapamycin (mTOR) Mutant Impairs the mTOR-mediated Signaling and Cardiac Function J. Biol. Chem., May 16, 2008; 283(20): 13842 - 13849. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Jacobshagen, M. Gruber, N. Teucher, A. G. Schmidt, B. W. Unsold, K. Toischer, P. Nguyen Van, L. S. Maier, H. Kogler, and G. Hasenfuss Celecoxib modulates hypertrophic signalling and prevents load-induced cardiac dysfunction Eur J Heart Fail, April 1, 2008; 10(4): 334 - 342. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. R. Kimball, A. N. D. Do, L. Kutzler, D. R. Cavener, and L. S. Jefferson Rapid Turnover of the mTOR Complex 1 (mTORC1) Repressor REDD1 and Activation of mTORC1 Signaling following Inhibition of Protein Synthesis J. Biol. Chem., February 8, 2008; 283(6): 3465 - 3475. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Sataranatarajan, M. M. Mariappan, M. J. Lee, D. Feliers, G. G. Choudhury, J. L. Barnes, and B. S. Kasinath Regulation of Elongation Phase of mRNA Translation in Diabetic Nephropathy: Amelioration by Rapamycin Am. J. Pathol., December 1, 2007; 171(6): 1733 - 1742. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Sharma, P. H. Guthrie, S. S. Chan, S. Haq, and H. Taegtmeyer Glucose phosphorylation is required for insulin-dependent mTOR signalling in the heart Cardiovasc Res, October 1, 2007; 76(1): 71 - 80. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Kuzman, T. D. O'Connell, and A. M. Gerdes Rapamycin Prevents Thyroid Hormone-Induced Cardiac Hypertrophy Endocrinology, July 1, 2007; 148(7): 3477 - 3484. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Padmasekar, R. Nandigama, M. Wartenberg, K.-D. Schluter, and H. Sauer The acute phase protein {alpha}2-macroglobulin induces rat ventricular cardiomyocyte hypertrophy via ERK1,2 and PI3-kinase/Akt pathways* Cardiovasc Res, July 1, 2007; 75(1): 118 - 128. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. E. Hannigan, J. G. Coles, and S. Dedhar Integrin-Linked Kinase at the Heart of Cardiac Contractility, Repair, and Disease Circ. Res., May 25, 2007; 100(10): 1408 - 1414. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Zhang, X. Xu, X. Hu, E. D. van Deel, G. Zhu, and Y. Chen Inducible Nitric Oxide Synthase Deficiency Protects the Heart From Systolic Overload-Induced Ventricular Hypertrophy and Congestive Heart Failure Circ. Res., April 13, 2007; 100(7): 1089 - 1098. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Sharma, I. C. Okere, M. K. Duda, D. J. Chess, K. M. O'Shea, and W. C. Stanley Potential impact of carbohydrate and fat intake on pathological left ventricular hypertrophy Cardiovasc Res, January 15, 2007; 73(2): 257 - 268. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. A. Nader, T. J. McLoughlin, and K. A. Esser mTOR function in skeletal muscle hypertrophy: increased ribosomal RNA via cell cycle regulators Am J Physiol Cell Physiol, December 1, 2005; 289(6): C1457 - C1465. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Luo, J. R. McMullen, C. L. Sobkiw, L. Zhang, A. L. Dorfman, M. C. Sherwood, M. N. Logsdon, J. W. Horner, R. A. DePinho, S. Izumo, et al. Class IA Phosphoinositide 3-Kinase Regulates Heart Size and Physiological Cardiac Hypertrophy Mol. Cell. Biol., November 1, 2005; 25(21): 9491 - 9502. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Hedhli, M. Pelat, and C. Depre Protein turnover in cardiac cell growth and survival Cardiovasc Res, November 1, 2005; 68(2): 186 - 196. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Ha, Y. Li, F. Hua, J. Ma, X. Gao, J. Kelley, A. Zhao, G. E. Haddad, D. L. Williams, I. William Browder, et al. Reduced cardiac hypertrophy in toll-like receptor 4-deficient mice following pressure overload Cardiovasc Res, November 1, 2005; 68(2): 224 - 234. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. ten Hove, C. A. Lygate, A. Fischer, J. E. Schneider, A. E. Sang, K. Hulbert, L. Sebag-Montefiore, H. Watkins, K. Clarke, D. Isbrandt, et al. Reduced Inotropic Reserve and Increased Susceptibility to Cardiac Ischemia/Reperfusion Injury in Phosphocreatine-Deficient Guanidinoacetate-N-Methyltransferase-Knockout Mice Circulation, May 17, 2005; 111(19): 2477 - 2485. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Schoffstall, A. Kataoka, A. Clark, and P. B. Chase Effects of Rapamycin on Cardiac and Skeletal Muscle Contraction and Crossbridge Cycling J. Pharmacol. Exp. Ther., January 1, 2005; 312(1): 12 - 18. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Cao, F. Kambe, L. C. Moeller, S. Refetoff, and H. Seo Thyroid Hormone Induces Rapid Activation of Akt/Protein Kinase B-Mammalian Target of Rapamycin-p70S6K Cascade through Phosphatidylinositol 3-Kinase in Human Fibroblasts Mol. Endocrinol., January 1, 2005; 19(1): 102 - 112. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. A. Hornberger, D. D. Armstrong, T. J. Koh, T. J. Burkholder, and K. A. Esser Intracellular signaling specificity in response to uniaxial vs. multiaxial stretch: implications for mechanotransduction Am J Physiol Cell Physiol, January 1, 2005; 288(1): C185 - C194. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Hafizi, X. Wang, A. H. Chester, M. H. Yacoub, and C. G. Proud ANG II activates effectors of mTOR via PI3-K signaling in human coronary smooth muscle cells Am J Physiol Heart Circ Physiol, September 1, 2004; 287(3): H1232 - H1238. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. G Proud Ras, PI3-kinase and mTOR signaling in cardiac hypertrophy Cardiovasc Res, August 15, 2004; 63(3): 403 - 413. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. R. McMullen, T. Shioi, L. Zhang, O. Tarnavski, M. C. Sherwood, A. L. Dorfman, S. Longnus, M. Pende, K. A. Martin, J. Blenis, et al. Deletion of Ribosomal S6 Kinases Does Not Attenuate Pathological, Physiological, or Insulin-Like Growth Factor 1 Receptor-Phosphoinositide 3-Kinase-Induced Cardiac Hypertrophy Mol. Cell. Biol., July 15, 2004; 24(14): 6231 - 6240. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Hernandez Left ventricular hypertrophy after renal transplantation: new approach to a deadly disorder Nephrol. Dial. Transplant., July 1, 2004; 19(7): 1682 - 1686. [Full Text] [PDF]
|
|
|
|
|
|
J. R. McMullen, M. C. Sherwood, O. Tarnavski, L. Zhang, A. L. Dorfman, T. Shioi, and S. Izumo Inhibition of mTOR Signaling With Rapamycin Regresses Established Cardiac Hypertrophy Induced by Pressure Overload Circulation, June 22, 2004; 109(24): 3050 - 3055. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Michael, S. Haq, X. Chen, E. Hsich, L. Cui, B. Walters, Z. Shao, K. Bhattacharya, H. Kilter, G. Huggins, et al. Glycogen Synthase Kinase-3{beta} Regulates Growth, Calcium Homeostasis, and Diastolic Function in the Heart J. Biol. Chem., May 14, 2004; 279(20): 21383 - 21393. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Frey, H. A. Katus, E. N. Olson, and J. A. Hill Hypertrophy of the Heart: A New Therapeutic Target? Circulation, April 6, 2004; 109(13): 1580 - 1589. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. Tarnavski, J. R. McMullen, M. Schinke, Q. Nie, S. Kong, and S. Izumo Mouse cardiac surgery: comprehensive techniques for the generation of mouse models of human diseases and their application for genomic studies Physiol Genomics, February 13, 2004; 16(3): 349 - 360. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. R. McMullen, T. Shioi, W.-Y. Huang, L. Zhang, O. Tarnavski, E. Bisping, M. Schinke, S. Kong, M. C. Sherwood, J. Brown, et al. The Insulin-like Growth Factor 1 Receptor Induces Physiological Heart Growth via the Phosphoinositide 3-Kinase(p110{alpha}) Pathway J. Biol. Chem., February 6, 2004; 279(6): 4782 - 4793. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. L. Yang, R. Gros, M. G. Kabir, A. Sadi, A. I. Gotlieb, M. Husain, and D. J. Stewart Conditional Cardiac Overexpression of Endothelin-1 Induces Inflammation and Dilated Cardiomyopathy in Mice Circulation, January 20, 2004; 109(2): 255 - 261. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Razeghi, S. Sharma, J. Ying, Y.-P. Li, S. Stepkowski, M. B. Reid, and H. Taegtmeyer Atrophic Remodeling of the Heart In Vivo Simultaneously Activates Pathways of Protein Synthesis and Degradation Circulation, November 18, 2003; 108(20): 2536 - 2541. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. R. McMullen, T. Shioi, L. Zhang, O. Tarnavski, M. C. Sherwood, P. M. Kang, and S. Izumo Phosphoinositide 3-kinase(p110{alpha}) plays a critical role for the induction of physiological, but not pathological, cardiac hypertrophy PNAS, October 14, 2003; 100(21): 12355 - 12360. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. N. Olson and M. D. Schneider Sizing up the heart: development redux in disease Genes & Dev., August 15, 2003; 17(16): 1937 - 1956. [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||